DOR BioPharma, Inc. (AMEX:DOR) ("DOR" or the "Company"), announced today that Gregory J. Davenport, Ph.D., President of DOR's BioDefense Division, will be presenting at the New York Society of Security Analysts, 8th Annual Healthcare Industry Conference in New York City. Dr. Davenport will be presenting during a special afternoon session focused on the biodefense sector.

Dr. Davenport will be providing an overview of the DOR's biodefense programs, including an update on the status and anticipated upcoming events relating to DOR's ricin and botulinum toxin vaccines. Dr. Davenport's presentation will occur on Wednesday, November 17, 2004, at 3:10pm ET at the Harvard Club, 27 West 44th St, New York, NY 10036.

A simultaneous live webcast of Dr. Davenport's audio/visual presentation may be accessed through DOR's website at http://www.dorbiopharma.com by logging onto DOR's website tomorrow, Wednesday, November 17, 2004 at approximately 3:00pm ET. A replay of the live webcast will be available on DOR's website for approximately 30 days following the webcast.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a biopharmaceutical company focused on the development of biodefense vaccines and therapeutics for areas of unmet medical needs. Through its BioDefense Division, DOR is developing bioengineered vaccines designed to protect against the deadly effects of ricin toxin and botulinum toxin. DOR's lead therapeutic product, orBec(R) (an oral formulation of beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of intestinal graft vs. host disease (iGvHD), a severe, life-threatening form of gastrointestinal inflammation. As previously announced, DOR completed the treatment phase of its pivotal Phase III clinical trial of orBec(R) and expects to announce top line results of this trial before the end of the year, and pending a positive outcome, filing an NDA for marketing authorization as early as April 2005. orBec(R) has been granted fast track status by the FDA for the treatment of iGVHD. For further information regarding DOR BioPharma, please visit the Company's website located at http://www.dorbiopharma.com.

This press release contains, and the webcast is expected to contain, forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma's current expectations about its future results, performance, prospects and opportunities. Where possible, DOR BioPharma has tried to identify these forward-looking statements by using words such as "anticipates," "believes", "intends", or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR BioPharma cannot assure you that it will be able to successfully develop or commercialize products based on its technology, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, that it will be able to maintain its listing on the American Stock Exchange, or that its business strategy will be successful. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR BioPharma's most recent reports on Form 10-QSB and Form 10-KSB. DOR BioPharma assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.